0.8174
Nucana Plc Adr stock is traded at $0.8174, with a volume of 129.86K.
It is down -3.83% in the last 24 hours and down -10.33% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$0.85
Open:
$0.87
24h Volume:
129.86K
Relative Volume:
1.17
Market Cap:
$4.91M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.051
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
-36.14%
1M Performance:
-10.33%
6M Performance:
-58.72%
1Y Performance:
-86.34%
Nucana Plc Adr Stock (NCNA) Company Profile
Compare NCNA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NCNA
Nucana Plc Adr
|
0.8174 | 4.91M | 0 | -33.44M | -28.30M | -16.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.50 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
582.50 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
558.18 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
240.09 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
241.06 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
Oct-22-20 | Initiated | Truist | Buy |
Jul-24-20 | Initiated | Oppenheimer | Outperform |
Aug-19-19 | Initiated | H.C. Wainwright | Buy |
Oct-19-18 | Initiated | Piper Jaffray | Overweight |
Oct-23-17 | Initiated | Citigroup | Buy |
Oct-23-17 | Initiated | Jefferies | Buy |
Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):